adalimumab products — Medica

Initial criteria

• age ≥ 18 years
• EITHER (a) trial of ≥ 3 months of one traditional systemic agent (methotrexate, cyclosporine, or acitretin, or PUVA) unless intolerant OR (b) contraindication to methotrexate
• prescribed by or in consultation with a dermatologist

Reauthorization criteria

• patient established on therapy ≥ 3 months
• beneficial clinical response (improvement from baseline in body surface area, erythema, thickness, or scale)
• improvement in symptom (pain, itching, burning) vs baseline

Approval duration

initial 3 months, reauth 1 year